Interleukin 6 in systemic sclerosis and potential implications for targeted therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22505699.
- Also identified by DOI 10.3899/jrheum.111423.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to review the potential importance of interleukin 6 (IL-6) in systemic sclerosis (SSc). PubMed and Scopus databases and American College of Rheumatology (from 2009-10) and European League Against Rheumatism abstracts (2009-11) were searched using keywords "scleroderma; SSc; cytokines; interleukins; interleukin 6" and publications were excluded if not pertaining to IL-6 in SSc. Data were extracted from selected articles to construct a cell interaction model of the effects of IL-6 in SSc. A total of 416 reports were found (PubMed, n = 82; Scopus, n = 331; 3 abstracts); 372 were excluded (irrelevant) leaving 41 publications and 3 abstracts (39 from PubMed, 18 from Scopus; but 16 were repeated from PubMed search), where 40 suggested IL-6 was important in SSc and 4 did not. Effects of IL-6 in SSc were summarized schematically. Of the 44 publications, 40 suggested that IL-6 may be important in SSc, allowing for a conceptual framework within SSc including effects on macrophages, fibroblasts, plasma cells, monocytes, and extracellular matrix.
Medical subject headings
- Interleukin-6
- Molecular Targeted Therapy
- Scleroderma, Systemic
- Interleukin-6 Inhibitors